Effects and Safety of Different Dose of Bambuterol on Chinese COPD Patients
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, 3-crossover trial with a 7-days washout baseline period
followed by three treatment periods of 21-days each performed in patients with COPD. Patients
will be randomized to receive three treatments (bambuterol 10mg, bambuterol 5 mg and
placebo).
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University
Collaborators:
Guangzhou First Municipal People’s Hospital Guangzhou First People's Hospital Nanfang Hospital of Southern Medical University